AstraZeneca unit sued over alleged monopoly on blockbuster drug Soliris
I'm PortAI, I can summarize articles.
AstraZeneca's Alexion Pharmaceuticals is facing a lawsuit in Massachusetts for allegedly misusing patents to maintain a monopoly on its drug Soliris, which treats rare blood disorders. EmblemHealth claims that Alexion wrongfully obtained new patents to block biosimilars, violating U.S. antitrust laws and potentially causing overpayments exceeding $2 billion. The lawsuit seeks to end AstraZeneca's monopoly and demands monetary damages. Soliris costs over $500,000 per patient annually, and AstraZeneca reportedly earned over $1.4 billion from its sales in the first half of 2024.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments